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Abstract
Background:  Genotyping of HBV is generally used for determining the epidemiological
relationship between various virus strains and origin of infection mostly in research studies. The
utility of genotyping for clinical applications is only beginning to gain importance. Whether HBV
genotyping will constitute part of the clinical evaluation of Hepatitis B patients depends largely on
the availability of the relevance of the evidence based information. Since Pakistan has a HBV
genotype distribution which has been considered less virulent as investigated by earlier studies
from south East Asian countries, a study on correlation between HBV genotypes and risk of
progression to further complex hepatic infection was much needed
Methods: A total of 295 patients with HBsAg positive were selected from the Pakistan Medical
Research Council's (PMRC) out patient clinics. Two hundred and twenty six (77%) were males,
sixty nine (23%) were females (M to F ratio 3.3:1).
Results: Out of 295 patients, 156 (53.2%) had Acute(CAH), 71 (24.2%) were HBV Carriers, 54
(18.4%) had Chronic liver disease (CLD) Hepatitis. 14 (4.7%) were Cirrhosis and HCC patients.
Genotype D was the most prevalent genotype in all categories of HBV patients, Acute (108),
Chronic (39), and Carrier (53).
Cirrhosis/HCC (7) were HBV/D positive. Genotype A was the second most prevalent with 28
(13%) in acute cases, 12 (22.2%) in chronics, 14 (19.7%) in carriers and 5 (41.7) in Cirrhosis/HCC
patients. Mixed genotype (A/D) was found in 20 (12.8%) of Acute patients, 3 (5.6%) of Chronic and
4 (5.6%) of carriers, none in case of severe liver conditions.
Conclusion: Mixed HBV genotypes A, D and A/D combination were present in all categories of
patients except that no A/D combination was detected in severe conditions. Genotype D was the
dominant genotype. However, genotype A was found to be more strongly associated with severe
liver disease. Mixed genotype (A/D) did not significantly appear to influence the clinical outcome.
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Background
HBV is a classical virus that has amazed the researchers
and clinicians around the world first with geographic rela-
tionship of its genotypes then secondly the association of
its different genotypes with a wide spectrum of clinical
manifestations. In the recent years, there has been an
explosion of knowledge regarding clinical significance of
HBV genotypes in terms of clinical outcomes and thera-
peutic response to antiviral therapy in patients with HBV
related severe liver conditions [1]. Approximately 2 bil-
lion people in the world are infected by HBV [2], More
than 350 million people are chronic carriers of the virus
[3] Acute hepatitis of varying severity exists in 95% of chil-
dren and 2–10 % of adult patients [4]. Overall, less than
1 % of acute infections lead to fulminant hepatitis and
death. Approximately 0–10 % of infected adults become
chronic carriers of HBV [5,6]. Chronic HBV infection is
currently the most common cause of cirrhosis and hepa-
tocellular carcinoma (HCC) in the world. Fifteen to 40%
of chronically infected people may develop cirrhosis and
HCC, the remaining individuals become asymptomatic
carriers. In perinatal transmission, there is a strong chance
for the child to become chronically infected compared to
the infection acquired during adulthood,(about 10% to
20%) [7,8].
Initially studies on the effect of genotypes on disease pro-
gression were reported from South-east Asian countries
where HBV is hyperendemic. Since genotypes B and C are
most prevalent in this region severity of liver dysfunction
was found associated with these genotypes. Patients
infected with genotype C were found having higher HBV-
DNA levels compared with those infected with genotype
B [9-11], A, and D [12], in some studies but not in others
[13,14]. Pakistan, according to WHO, falls in the low
endemic area of HBV infection with prevalence of 3%
infected population. Studies from Pakistan focused more
towards the HBV prevalence rate [15,16], epidemiological
issues [17], genotyping of most prevalent strain and its
genetic variability regarding core region.[18] Since the
most prevalent genotype is D [18] coexisting with less
prevalent genotype A and A+D less than 20% [19], it was
required to investigate the virulence of these genotypes,
especially regarding genotype D which has been found as
less virulent and genotype of the asymptomatic carriers by
earlier studies from south East Asian countries. This
research study was conducted to assess the correlation
between HBV genotype D, A and A+D and risk of progres-
sion to further complex hepatic infections such as chronic,
acute, cirrhosis and HCC.
Results
Two hundred and ninety five HBsAg positive registered
patients were selected from the PMRC OPD. Two hundred
and twenty six (76.6%) were males, 69 (23.4%) were
females (M to F ratio 3.3:1) Table 2. Out of 293, 156
(53%) had Acute (CAH), 71 (24%) were HBV Carriers,
54(18.3%) had Chronic(CLD) Hepatitis, Cirrhosis and
HCC patients were 14 (4.7%). Generally, genotype D
(Figure 1) was the most prevalent genotype in all catego-
ries of HBV patients, Acute (69.2%), Chronic (72.2%),
Carrier (74.7%)). Cirrhosis/HCC (62.2%) were HBV/D
positive. Genotype A was the second prevalent with 28
(13%) in acute cases, 12 (22.2%) in chronics,14 (19.7%)
in carriers and 5 (37.7.8%) in Cirrhosis/HCC patients.
Mixed genotype A+D was found in 20 (12.8%) of Acute
patients, 3 (5.6%) of Chronic and 4(5.6%) of carriers
(Table 3).
Discussion
This is the first study from Pakistancomparing the clinical
outcome of HBV-related liver disease in patients infected
with different HBV genotypes using a PCR based method.
Out of 295 HBsAg positive registered patients, 225 (77%)
were males, and 69 (23%) were females (M to F ratio
approximately 3.3:1) who were suffering from various
liver conditions were genotyped (Table 2). Genotype A, D
and both A and D (figure 1) were present in all categories
of HBV patients but the most prevalent genotype was D in
all conditions except cirrhosis in which genotype A was
dominant. This pattern of genotype prevalence in Paki-
stan is in accordance with studies from South East Asia,
especially countries sharing borders with Pakistan such as
Afghanistan, Iran and India having dominance of geno-
type D. Chattopadhyay [21] reports, in a similar study
from India that Genotypes D and A were present in all
CLDB patient categories and genotype D was dominant.
Generally, apart from HBV genotype B and C there is lack
of information about the clinical course of HBV infected
patients with other genotypes.
3% agarose gel showing genotype specific bands in patients  infected with hepatitis B virus Figure 1
3% agarose gel showing genotype specific bands in patients 
infected with hepatitis B virus. Lane 1 and 2 show HBV geno-
type A specific 68 bp band; Lane 3 show 100 bp marker; Lane 
4,5 and 6 show HBV genotype D specific 119 bp band.Virology Journal 2007, 4:128 http://www.virologyj.com/content/4/1/128
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The clinical significance of different HBV genotypes has
become increasingly recognized in patients with acute and
chronic infection [22]. Genotyping of Acute patients in
this study revealed genotype D(69.2%) as most prevalent
genotype, whereas, A and AD were 18.0% and 12.8%
respectively. There is paucity of information on the corre-
lation between HBV genotypes and outcome of acute HBV
infection. Acute HBV infection in Europe in earlier studies
was found to be associated with genotype D [23,24], but
recently it has been demonstrated that A is the most prev-
alent amongst the patients with acute Hepatitis B [25].
Similarly a study from Japan demonstrates HBV genotype
A in patients with acute hepatitis B where the most preva-
lent genotype Band C lead to chronic infection [26]. This
leads us to believe that different genotypes may be associ-
ated with different rates of progression from acute to
chronic HBV infection. If we conclude that these reports
are possibly not reflecting the geographical difference but
instead are showing the most prevalent genotype as most
virulent as in the case of Europe then why is genotype A
more common in Acute infection in Japanese patients
when it should be B or C.
In Chronic infection levels of viremia are generally low.
The strong determinant of chronicity is age at the time of
infection. Long-term prognosis is poorer among HBeAg-
negative individuals compared to their counterparts who
are HBeAg-positive. In this study 18.4% had Chronic
(CLD) Hepatitis. Out of 54 chronic patients, 72.2% had
genotype D, 22.2% had A and 5.6% had AD. This is in
contrast to a study by Mayerat et al. [23] which suggested
that the chronic infection by HBV could be more fre-
quently associated with genotype A than genotype D.
Whereas, genotype D was more prevalent among patients
with resolving acute HBV infection, suggesting that HBV
genotype D was associated with a lower rate of chronic
HBV infection; however, Erhardt et al.'s [27] study on
comparison of HBV genotypes A and D report that the rate
of interferon-induced HBeAg seroconversion was lower
among patients with genotype D than among those with
genotype A (6% vs. 37%), whereas, the influence of these
genotypes on acute HBV infection was inconclusive. HBV
genotype D has also been described as the genotype of
intravenous illicit drug users [28].
During the Carrier state, low HBsAg levels are marked by
HBeAg negativity with anti-HBe positivity, low HBV DNA
level and repeatedly normal ALT. In this study the highest
prevalence of Genotype D was found in HBV asympto-
matic carriers (74.7%). Borchani [29] also reports that
Table 1: Diagnosis according to gender in different categories of patients
Diagnosis Male (n = 226) (76.6%) Female (n = 69) (23.4%) Total (n = 295)
Number Percent Number Percent Number Percent
Acute (CAH) 124 54.86 32 46.3 156 52.7
Chronic (CLD) 43 19.0 11 16.0 54 18.2
Carrier 48 21.2 23 33.3 71 24
Cirrhosis/HCC 11 4.8 3 4.3 14 4.7
Table 2: Genotype distribution according to disease and gender
Diagnosis/Genotype Male n = 226(76.6%) Female n = 69(23.4%) Total (n = 295)
Acute (CAH) 124 32 156(52.9%)
Genotype D 88 (71.0%) 20 (62.5%) 108 (69.2%)
A 23 (18.5%) 5 (15.6%) 28 (18.0%)
AD 13 (10.5%) 7 (21.9%) 20 (12.8%)
Chronic (CLD) 43 11 54(18.3%)
Genotype D 30 (69.8%) 9 (81.8%) 39 (72.2%)
A 10 (23.3%) 2 (18.2%) 12 (22.2%)
AD 3 (6.9%) - 3 (5.6%)
Carrier (asymptomatic) 48 23 71(24%)
Genotype D 38 (79.2%) 15 (65.2%) 53 (74.7%)
A 6 (12.5%) 8 (34.8%) 14 (19.7%)
AD 4 (8.3%) - 4 (5.6%)
Cirrhosis/HCC 11 3 14(4.7%)
Genotype D 7 (63.6%) 1(33.3% 8 (57.14%)
A 4(36.3%) 2 (66.6%) 6 (43.8%)
A D ---Virology Journal 2007, 4:128 http://www.virologyj.com/content/4/1/128
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Genotype D as the most prevalent amongst theie Asymp-
tomatic Carrier patients (67.2%). A study in Italy has
found that carriers of HBsAg who are symptom-free and
whose liver function tests are normal have an excellent
prognosis and the risk of hepatocellular carcinoma was
low over the mean follow-up period of about 30 years
[30]. The prognosis of the inactive carrier is generally
good and well supported by long-term follow-up studies
[31-33]. An estimated 20% to 30% of HBsAg carriers may
develop reactivation of hepatitis B with elevation of bio-
chemical levels, high serum DNA level with or without
sero-reversion to HBeAg. Recurrent episodes of reactiva-
tion or sustained reactivation can occur and contribute to
progressive liver disease and decompensation especially,
in the immunosuppressed individuals. Frequently, HBV
reactivation is usually asymptomatic, but it may mimic
acute viral hepatitis [34].
Cirrhosis and Hepatocellular Carcinoma (HCC) are two
major long-term complications of chronic HBV infection
which developed in 14 of our patients (11 males and 3
females). Five had developed cirrhosis and 9 hepatocellu-
lar carcinoma. Chronically infected subjects have a 100
times increased risk of hepatocellular carcinoma com-
pared to non-carriers. HBsAg positivity increases risk of
developing HCC by 10 folds and HBeAg positivity by 60
folds, whereas, a detectable HBV DNA level yields a 4 fold
increased risk of HCC [35]. Regarding the genotype distri-
bution in this study HBV genotype D was most prevalent
among the HCC patients and genotype A in cirrhosis
patients. Four out of five Cirrhosis patients in this study
had HBV genotype A. A similar study from Spain [36]
reports genotype A as more virulent because earlier the
core antigen seroconversion rates were similar with geno-
types A and D, but sustained biochemical and virological
remission was not common with patients with genotype
A who had HBeAg seroconversion. These patients had also
higher rates of HBsAg clearance. These results indicate that
HBV genotype A is associated with more marked ALT ele-
vation, a higher rate of HBeAg positivity and presence of
liver cirrhosis.[37]. Thus, it would be interesting to specu-
late that HBV genotype A could indeed be more prone to
chronic infection than genotype D [38].
Among the nine patients in this study who developed
HCC two were females and seven were males. Age ranged
from 35 yrs to 68 yrs. Genotype D being most prevalent
was present in 7(77.7%) patients, whereas genotype A in
two patients, who developed HCC from chronic infection.
Out of 5 with genotype D, five males, age range 50 yrs to
68 yrs, were long time carriers (fifteen years after suffering
from HBV infection) and the rest of the two, one male and
other female were in the age range 35 yrs and 45 yrs.
Thakur et al. [39] also concluded that genotype D may
predict the occurrence of hepatocellular carcinoma in
young Indian patients. Several studies have indicated that
older age (> 45 years) is an important determinant of
HCC. Having a first degree relative with HCC, the pres-
ence of cirrhosis, and reversion activity, all contribute to
HCC development [40,41]. In this study, all patients with
HCC were above 50 years of age but among the 5 patients
who developed cirrhosis the age ranged from 22 years to
60 years. Kumar et al [37], also reports cirrhosis of liver to
be more frequently in patients aged 25 years and above.
Generally, all categories of liver diseases showed male
dominance, especially in HCC it is well documented.
HCC incidence is three to six times higher in males than
in females, suggesting a tumorigenic effect of androgens
[42,43]. The 5 patients who developed cirrhosis from
chronic condition were one female and 4 males again
showing the predominance of male gender. In an experi-
mentally induced carcinomas spontaneous neoplasms
occurred at a higher rate in male rats and mice [44]. The
studies on estradiol showed not only suppressive effect of
estradiol on chemical hepatocarcinogenesis in rats [45]
but also its cytoprotective effect against hepatocyte injury
[46]. Thus it can be concluded that a better understanding
of the biological mechanisms underlying the gender-asso-
ciated differences observed in chronic HBV infection may
provide valuable information on more effective treatment
modalities in liver disease in both males and females [47].
Combination of AD exist where ever genotype A and D are
prevalent such as India [39], Italy [48] etc. but none of
studies report any virulence associated to it. In this study
though AD combination was present in 12% of acute
Table 3: Primer sequences used for HBV genotyping by nested PCR (position, specificity, and polarity). An "M " represents a 
nucleotide that could be either an A or a C; a "Y" represents a nucleotide that could be either a C or a T. nt, nucleotide.
Primers Sequence Gene/CDS Product
Step-one PCR P1b universal, sense) 5'-TCA CCA TAT TCT TGG GAA CAA GA-3' nt2823-2845, 1065 bp
S1-2 universal, antisense) 5'-CGA ACC ACT GAA CAA ATG GC-3' nt685-704,
Step-two PCR B2 sense 5'-GGC TCM AGT TCM GGA ACA GT-3' nt67-86, types A specific, to E
Mix A BAIR antisense 5'-CTC GCG GAG ATT GAC GAG ATG T-3' nt113-134, type A specific, 68 bp
BBIR antisense 5'-CAG GTT GGT GAG TGA CTG GAG A-3' nt324-345, type B specific, 122 bp
BCIR antisense) 5'-GGT CCT AGG AAT CCT GAT GTT G-3' nt165-186, type C specific, 281 bpVirology Journal 2007, 4:128 http://www.virologyj.com/content/4/1/128
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patients, 5.6% of chronic patients and 5.6% of carriers,
but none of the cirrhosis or HCC patients had combina-
tion of AD.
Gerner et al. [49] observed that patients who were infected
with HBV genotype A, after treatment with interferon and
a relapse, had a switch of the genotype from HBV geno-
type A to D, whereas, Chen [50] observed that the domi-
nant-genotype C changed to genotype Ba after anti-HBV e
antigen (anti-HBe) seroconversion. Originally HBV/Ba
(B2) co-existed as a minor population with HBV/C during
the early course of acute HBV infection and then emerged
and gradually became the dominant genotype. In our
patients since the genotype was not checked before they
developed severe conditions therefore, it can not be ascer-
tained whether there was a switch of genotype. The mech-
anism for this recombination and switching remains
enigmatic but this could be a possibility that long term
sequelae could lead to reorganization of nucleotides. It is,
hence, better advised that all HBV infected patients,
regardless of status, should get screened after every 6
months with alpha-fetoprotein (AFP) and liver sonogram.
Conclusion
Genotyping of HBV may remain a research tool unless we
prove that it can predict the risk of adverse outcomes (ful-
minant disease, cirrhosis, HCC) or can influence decision-
making in managing these conditions. Studies so far
around the world have lead us to believe that different
genotypes may be associated with different rates of pro-
gression from acute to chronic HBV infection. However,
differences in host and environmental factors make it dif-
ficult to extrapolate findings from one geographical
region to another. Therefore, larger, in-depth longitudinal
prospective studies are necessary, in various regions of the
world, that could provide more information on the rela-
tionship of HBV genotypes to the severity of liver disease
and thereby clinical outcome.
Methods
Selection of subjects
HBsAg positive 295 registered patients wereselected. irre-
spective of age and gender, with HBV-related liver disease
such as Acute, Chronic, Cirrhosis, HCC, attending the out-
patient Department of Pakistan Medical and Research
Council(PMRC), Gastroenterology unit JPMC during the
years 2006 to 2007, were selected for the study. All
patients were HBV positive, registered patients Clinical
data were retrieved from medical records, as were labora-
tory test results including hemogram, liver function tests,
coagulation profile, and findings at abdominal ultra-
sonography, upper gastrointestinal endoscopy and liver
biopsy. Liver cirrhosis and HCC were diagnosed either on
the basis of histology, or on a combination of radiologi-
cal, endoscopic and laboratory data. Serum samples were
collected from the study patients when they came for the
follow-up. A written as well as verbal informed consent
was taken from each subject; however, in case of patients
who were under the age of 18, parental consent was
obtained. Prior to this approval of ZMUH ethical review
committee was obtained. The following inclusion and
exclusion criteria were applied while selecting patients for
this study:
Inclusion Criteria
All healthy and diseased HbsAg positive individuals
(healthy carriers, acute hepatitis, chronic hepatitis).
Exclusion Criteria
Patients with other hepatic viral markers (A, C, D, E) with
HBV were excluded.
DNA extraction
DNA extraction from serum was done by DNA extraction
kit (Promega Minipreps). The HBV genome was amplified
by nested PCR using the universal primers (P1 and S1-2)
for the outer primers, followed by two different mixtures
containing type-specific inner primers as described above.
PCR Amplification
A modified version of nested PCR developed by Naito et
al. [20] was followed. The sequences of PCR primers(sup-
plied by Gene Link USA) used in this study were in the
form of pairs step one and step-two designed on the basis
of the conserved nature of nucleotide sequences in regions
of the pre-S1 through S genes, irrespective of theHBV gen-
otypes (Figure 1). The HBV genome was amplified by
sequence specific PCR using the universal primers (P1 and
S1-2) for the outer primers, followed by two different mix-
tures containing type-specific inner primers as described
in Table 1.
Primer sequence and detail
Step one PCR
The first PCR was carried out in a tube containing 50 µl of
a reaction buffer made up of the following components:
50 ng each of the outer primer, a 200 µM concentration of
each of the four deoxynucleotides, 1U of Taq DNA
polymerase (Perkin-Elmer, Norwalk, Conn.), and 1× PCR
buffer containing 1.5 mM MgCl2. The extracted DNA was
given an initial 10 min incubation at 95°C for a hot start
reaction. After 10 min the PCR program was paused to dis-
pense the master-mix in all tubes. The thermocycler
(GeneAmp PCR system 2400,9600, and 9700A; Perkin-
Elmer) was programmed to first incubate the samples for
10 min at 95°C, followed by 35 cycles consisting of 94°C
for min., 94°C for 20s, 55°C for 20s, and 72°C for 1 min.
with a final extension of 5 min. at 72°C and 4°C.Virology Journal 2007, 4:128 http://www.virologyj.com/content/4/1/128
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Step two PCR
Two second-round PCRs were performed for each sample,
with the common universal sense primer (B2) and mix A
for types A through C and the common universal anti-
sense primer (B2R) and mix B for types D through F.A 2.5
µl aliquot of the first PCR product was added to two tubes
containing the second sets of each of the inner primer
pairs, each of the deoxynucleotides, AmpliTaq Gold DNA
polymerase, and PCR buffer, as in the first reaction. These
were amplified for35 cycles with the following parame-
ters: preheating at 94°C for 3 min, 15 cycles of amplifica-
tion at 94°C for 20s, 58°C for 30s, and 72°C for 40s, and
an additional 20 cycles of 94°C for 30s, 60°C for 30s, and
72°C for 45s with an extension of 7 min at 72°C and
incubation at 4°C. Genotypes of HBV for each sample
were determined by identifying the genotype-specific
DNA bands. The two different second-round PCR prod-
ucts from one sample were separately electrophoresed on
a 3% agarose gel,(1% agarose plus 2% Nusieve Agarose)
stained with ethidium bromide, and evaluated under UV
light. The sizes of PCR products were estimated according
to the migration pattern of a 50-bp DNA ladder (Pharma-
cia Biotech, Uppsala, Sweden).
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